featured
Lapatinib Plus Capecitabine in Patients With Previously Untreated Brain Metastases from HER2-positive Metastatic Breast Cancer (LANDSCAPE): A Single-group Phase 2 Study
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study
Lancet Oncol 2012 Nov 01;[EPub Ahead of Print], T Bachelot, G Romieu, M Campone, V Diéras, C Cropet, F Dalenc, M Jimenez, Rhun Le, JY Pierga, A Gonçalves, M Leheurteur, J Domont, M Gutierrez, H Curé, JM Ferrero, C Labbe-DevilliersFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.